Valproate and palmitate binding to serum albumin in valproate-treated patients. Relation to obesity.
Binding of valproate and palmitate to serum albumin was studied in 29 valproate-treated epileptic patients. The results were compared with similar observations in a reference group of 43 non valproate-treated individuals. The binding affinity for palmitate was decreased (P < 0.0001) resulting in increased availability of long-chain fatty acids (P = 0.008) due to competitive valproate binding in the valproate-treated patients. The findings support a hypothesis on the pathogenesis of obesity as a complication of valproate treatment of epilepsy.
Vorum
H
H
Institute of Medical Biochemistry, University of Aarhus, Denmark.
Gram
L
L
Honoré
B
B
D000328:Adult; D015992:Body Mass Index; D004827:Epilepsy / Q000097:blood* / Q000150:complications / Q000188:drug therapy; D005230:Fatty Acids, Nonesterified / Q000097:blood; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008954:Models, Biological; D009765:Obesity / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D019308:Palmitic Acid; D010169:Palmitic Acids / Q000097:blood*; D011485:Protein Binding; D012709:Serum Albumin / Q000378:metabolism*; D014635:Valproic Acid / Q000097:blood* / Q000627:therapeutic use*
D005230:Fatty Acids, Nonesterified; D010169:Palmitic Acids; D012709:Serum Albumin; D019308:Palmitic Acid; D014635:Valproic Acid